<DOC>
	<DOCNO>NCT01710839</DOCNO>
	<brief_summary>To see Lucentis 0.5mg combine Targeted Pan Retinal photocoagulation decrease total number intravitreal injection year ischemic central retinal vein occlusion , hemi-retinal vein occlusion branch retinal vein occlusion compare standard care</brief_summary>
	<brief_title>Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections Treatment Ischemic Central Retinal Vein Occlusion , Hemi Retinal Vein Occlusion , Branch Retinal Vein Occlusion</brief_title>
	<detailed_description>The WAVE trial phase IV , open label , 12-month trial intravitreal ranibizumab 0.5 mg patient ( n=30 ) ischemic CRVO , HRVO BRVO previously treat ranibizumab anti-VEGF intravitreal injection therapy , incomplete responder 2 consecutive intravitreal anti-VEGF injection past 4 month . Randomization 1:4 , 1=control , ranibizumab , 4=treatment arm . In total , 6 subject randomize control 24 randomize treatment arm . Cohort 1- 24 Subjects previously treat Patients receive 6 dos ranibizumab 0.5 mg , follow PRN intravitreal injection ranibizumab 0.5 mg base pre-defined retreatment criterion 11 total injection . Wide field angiography guide peripheral targeted-retinal photocoagulation ( TRP ) , divide 2 session need , one 2 week post injection visit another later M4/V7 , repeat wide field angiogram indicate area sufficiently treat first TRP session Cohort 2- 6 Subjects , previously treat patient receive 6 dos ranibizumab 0.5 mg , follow PRN intravitreal injection ranibizumab 0.5 mg base pre-defined retreatment criterion 11 total injection .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age &gt; 18 year Visual acuity 20/25 20/800 , ETDRS best correct visual acuity Ability provide write informed consent comply study assessment full duration study Patients previously treat ITV antiVEGF : â€¢ With least 2 consecutive monthly intravitreal injection antiVEGF medication presence persistent recurrent macular edema past 4 month IOP 30 mm Hg Any previous retinal laser photocoagulation study eye Previous intravitreal injection study eye corticosteroid treatment Previous vitrectomy study eye ( posterior anterior associate vitreous loss cataract surgery ) Intracapsular cataract extraction Any previous radiation treatment head/neck principal sub investigator feel clinically relevant Inability ass iris angle neovascularization ( corneal opacity preclude gonioscopy ) Significant cardiovascular disease cancer would prevent followup visit completion 12 month study Significant diabetic retinopathy fellow eye ( diabetic macular edema , proliferative diabetic retinopathy , highrisk nonproliferative diabetic retinopathy ) Participation another simultaneous medical investigator trial Ocular disorder concurrent disease study eye may confound interpretation study result , compromise visual acuity require medical surgical intervention , include history retinal detachment , macular hole , choroidal neovascularization cause ( e.g. , DME , AMD , ocular histoplasmosis , pathologic myopia ) Structural damage center macula study eye prior CRVO , HRVO BRVO likely preclude improvement visual acuity follow resolution macular edema , include atrophy retinal pigment epithelium , subretinal fibrosis , laser scar ( ) Vitreomacular traction clinically significant epiretinal membrane study eye evident biomicroscopically OCT ( vitreomacular attachment OK ) Infectious blepharitis , keratitis , scleritis , conjunctivitis ( either eye ) current treatment serious systemic infection Spherical equivalent refractive error study eye 8 diopter myopia ( For patient refractive cataract surgery study eye , preoperative spherical equivalent refractive error 8 diopter myopia allow ) Uncontrolled Blood pressure : define systolic pressure &gt; 180mmHg and/or diastolic pressure &gt; 110 mm Hg ( sit ) screen period Uncontrolled diabetes mellitus Renal failure require dialysis renal transplant Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . History disease , metabolic dysfunction , physical examination finding , finding give reasonable suspicion disease condition contraindicate use investigational drug , might affect interpretation result study , render subject high risk treatment complication History allergy fluorescein , amenable treatment Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze principal investigator ( PI ) and/or subinvestigator . History allergy humanize antibody component ranibizumab formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>CRVO</keyword>
	<keyword>BRVO</keyword>
	<keyword>HRVO</keyword>
	<keyword>Macular edema</keyword>
	<keyword>vein occlusion</keyword>
</DOC>